Semaglutide in Canada: Ozempic, Wegovy, Rybelsus, Sevmia and the generics

Semaglutide is one ingredient sold in Canada under several product names, for different conditions, in different presentations, with different regulatory statuses. Mixing them up is the most common mistake in the questions this site was built to answer. This page maps ingredient to product to indication, from the current Health Canada Drug Product Database records and product monographs.

The short version

• Ozempic and the four generic injections (Apotex, Dr. Reddy's, two Aspen products) are for type 2 diabetes. None has a Canadian weight-management indication.
• Wegovy is for chronic weight management (adults, and adolescents 12 to under 18), for reducing non-fatal heart attack risk in adults with established cardiovascular disease, and conditionally for MASH.
• Sevmia (Apotex) is the first generic semaglutide for chronic weight management, authorized 29 June 2026. Its DPD status is Approved, not Marketed, and it comes as one pen delivering 1 mg doses only. The monograph says other doses need other products.
• Rybelsus is the oral tablet, for type 2 diabetes, with a cardiovascular indication added at the end of 2025 and new 1.5, 4 and 9 mg strengths marketed in March 2026.
• Plosbrio and Poviztra are additional product names for the Novo Nordisk biologics (Ozempic and Wegovy respectively), approved but not marketed. They are not generics.
• Two Aspen products are Approved but not Marketed. One Dr. Reddy's recall (August 2026) is lot-specific and does not change the DPD status.

At a glance

A DPD status says whether a product is authorized and whether the company reports it as sold. It does not say whether a pharmacy has it, whether a plan pays for it, or whether it suits anyone. Coverage is on the coverage page.

Status words, in order

Health Canada authorizes a product and issues a DIN. The DPD then records whether it is Marketed, Approved (authorized but not yet sold), Dormant or Cancelled. None of that says whether a pharmacy has it. Public coverage and interchangeability are provincial decisions made after all of this. See the coverage record.

Product records

Under review or investigational

Not authorized in Canada. Listed so that a reader who has heard the names knows where they stand.

Health Canada has warned about fake and unauthorized GLP-1 products and about unauthorized peptides sold online. A-C14 A-C13

The published studies

Twenty semaglutide studies are explained in plain language in the evidence library, plus the stopping and safety sections.

Topics to raise with a clinician

Not advice; a list of things worth asking about, drawn from the monographs and Health Canada notices: contraindications specific to each product; the aspiration-risk review for GLP-1 therapies before general anesthesia or deep sedation; what happens to weight after stopping (see the stopping and weight regain studies); and how the indication on the label matches the reason for the prescription. A-C42